AMAG’s Turnaround Plans Hit A Snag With Feraheme CRL
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA declined to approve the I.V. iron in a broad patient population and requested another clinical trial to further evaluate safety. The decision gives rival Daiichi more time to penetrate the market with its I.V. iron Injectafer.
You may also be interested in...
FDA Trial Design Challenge: Does Same Indication Demand Same Kind Of Study?
Luitpold citizen petition seeking to block AMAG’s expanded indication for injectable iron offers FDA an opportunity to weigh in on how similar trial designs must be for drugs with the same indication.
A New Course For AMAG: Expanding Feraheme And Moving Beyond Iron
AMAG is looking to build out its portfolio by in-licensing or acquiring new commercial products that complement its I.V. iron product Feraheme. The company is in negotiations for multiple assets, while at the same time preparing to launch Feraheme into a broader patient population.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: